Immunogenicity and Safety of Vaccinations in Immunocompromised Persons

CompletedOBSERVATIONAL
Enrollment

645

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

February 29, 2016

Conditions
Arthritis, RheumatoidSpondylarthritisVasculitis
Interventions
BIOLOGICAL

Hepatitis A vaccine and tetanus vaccine

Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study

Trial Locations (10)

1211

University of Geneva, University Hospitals, Division of Rheumatology, Geneva

University of Geneva, University Hospitals, Service de Médecine Tropicale et Humanitaire, Geneva

3010

University of Bern, Inselspital, Division of Infectious Diseases and Travel Medicine, Bern

University of Bern, Inselspital, Division of Rheumatology, Bern

4031

University Hospital of Basel, Rheumatology Division, Basel

4051

Swiss Tropical and Public Health Institute, Basel

5001

Cantonal Hospital Aarau, Division of Rheumatology, Aarau

8001

University of Zurich, Epidemiology, Biostatistics and Prevention Institute, Divison of Infectious Diseases, Zurich

8091

University of Zurich, University Hopsital, Divison of Rheumatology, Zurich

9007

Cantonal Hospital St. Gallen, Division of Rheumatology, Sankt Gallen

All Listed Sponsors
collaborator

University of Basel

OTHER

collaborator

Swiss Tropical & Public Health Institute

OTHER

collaborator

University of Bern

OTHER

collaborator

University Hospital, Geneva

OTHER

collaborator

Cantonal Hospital of St. Gallen

OTHER

collaborator

Cantonal Hospital of Aarau, Switzerland

OTHER

lead

University of Zurich

OTHER

NCT01947465 - Immunogenicity and Safety of Vaccinations in Immunocompromised Persons | Biotech Hunter | Biotech Hunter